Literature DB >> 17766564

Relationships among subjective and objective measures of adherence to oral antipsychotic medications.

Dawn I Velligan1, Mei Wang, Pamela Diamond, David C Glahn, Desiree Castillo, Scott Bendle, Y W Francis Lam, Larry Ereshefsky, Alexander L Miller.   

Abstract

OBJECTIVE: The most common ways of assessing adherence to oral antipsychotic medications in research and in clinical practice are self-report and physician report. This prospective study examined the agreement among measures of adherence to oral antipsychotic medications among 52 outpatients with schizophrenia.
METHODS: Participants were assessed at baseline during a visit to their outpatient clinic and followed for 12 weeks. Adherence was assessed by using subjective measures (self-report and physician report) and objective measures (pill counts conducted in the home, electronic monitoring, and blood plasma concentrations). Electronic monitoring was used as an imperfect standard against which other methods were judged.
RESULTS: Data from pill counts and from electronic monitoring were strongly correlated (r(k)=.61). Self-report and physicians' ratings of compliance were weakly correlated with pill count and electronic monitoring when compliance scores were examined with rank-order correlations (r(k)=.18-.32). When the sample was dichotomized into adherent and nonadherent groups on the basis of electronic monitoring or pill count (at least 80% adherent), neither physicians nor patients identified adherent behavior (kappa<or=20). Blood plasma concentrations were not correlated with any other measures of adherence (kappa<or=20). Self-report and physician report were best correlated with clinical state (r(k)=-.27, r(k)=-.25), suggesting that patients and treating professionals may use clinical state to estimate adherence.
CONCLUSIONS: Patients and physicians were not able to identify adherence. The inability of physicians to accurately identify adherent individuals is likely to have important consequences for prescribing behavior, health care costs, and patient outcomes.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17766564     DOI: 10.1176/ps.2007.58.9.1187

Source DB:  PubMed          Journal:  Psychiatr Serv        ISSN: 1075-2730            Impact factor:   3.084


  85 in total

Review 1.  Concordance of adherence measurement using self-reported adherence questionnaires and medication monitoring devices.

Authors:  Lizheng Shi; Jinan Liu; Yordanka Koleva; Vivian Fonseca; Anupama Kalsekar; Manjiri Pawaskar
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

Review 2.  Self-report measures of medication adherence behavior: recommendations on optimal use.

Authors:  Michael J Stirratt; Jacqueline Dunbar-Jacob; Heidi M Crane; Jane M Simoni; Susan Czajkowski; Marisa E Hilliard; James E Aikens; Christine M Hunter; Dawn I Velligan; Kristen Huntley; Gbenga Ogedegbe; Cynthia S Rand; Eleanor Schron; Wendy J Nilsen
Journal:  Transl Behav Med       Date:  2015-07-09       Impact factor: 3.046

3.  A comparison of various methods of measuring antidepressant medication adherence among children and adolescents with major depressive disorder in a 12-week open trial of fluoxetine.

Authors:  Paul A Nakonezny; Carroll W Hughes; Taryn L Mayes; Kathryn H Sternweis-Yang; Betsy D Kennard; Matthew J Byerly; Graham J Emslie
Journal:  J Child Adolesc Psychopharmacol       Date:  2010-10       Impact factor: 2.576

4.  The use of individually tailored environmental supports to improve medication adherence and outcomes in schizophrenia.

Authors:  Dawn I Velligan; Pamela M Diamond; Jim Mintz; Natalie Maples; Xueying Li; John Zeber; Larry Ereshefsky; Yui-Wing F Lam; Desiree Castillo; Alexander L Miller
Journal:  Schizophr Bull       Date:  2007-10-10       Impact factor: 9.306

Review 5.  Tactics and technologies to manage nonadherence in patients with schizophrenia.

Authors:  William M Glazer; Mathew J Byerly
Journal:  Curr Psychiatry Rep       Date:  2008-08       Impact factor: 5.285

6.  Non-adherence to medication in patients with psychotic disorders: epidemiology, contributing factors and management strategies.

Authors:  John M Kane; Taishiro Kishimoto; Christoph U Correll
Journal:  World Psychiatry       Date:  2013-10       Impact factor: 49.548

Review 7.  [Long-acting injectable antipsychotics. Overview and advice for daily routine care].

Authors:  S Köhler; A Heinz; P Sterzer
Journal:  Nervenarzt       Date:  2014-09       Impact factor: 1.214

Review 8.  Psychotropic medication nonadherence among United States Latinos: a comprehensive literature review.

Authors:  Nicole M Lanouette; David P Folsom; Andres Sciolla; Dilip V Jeste
Journal:  Psychiatr Serv       Date:  2009-02       Impact factor: 3.084

9.  Prospective trial of customized adherence enhancement plus long-acting injectable antipsychotic medication in homeless or recently homeless individuals with schizophrenia or schizoaffective disorder.

Authors:  Martha Sajatovic; Jennifer Levin; Luis F Ramirez; David Y Hahn; Curtis Tatsuoka; Christopher S Bialko; Kristin A Cassidy; Edna Fuentes-Casiano; Tiffany D Williams
Journal:  J Clin Psychiatry       Date:  2013-12       Impact factor: 4.384

10.  Long-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trials.

Authors:  Taishiro Kishimoto; Alfred Robenzadeh; Claudia Leucht; Stefan Leucht; Koichiro Watanabe; Masaru Mimura; Michael Borenstein; John M Kane; Christoph U Correll
Journal:  Schizophr Bull       Date:  2012-12-17       Impact factor: 9.306

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.